Abstract
Rationale
Schizophrenia is a devastating mental disease that affects nearly 1% of the population worldwide. It is well documented that the dopaminergic (DAergic) system is compromised in schizophrenia. It is of note that the mixed dopamine (DA) D1/D2 receptor agonist apomorphine induces schizophrenia-like symptoms in rodents, including disruption of memory abilities. Neuroactive steroids, comprising dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulphate (DHEAS), were shown to affect brain DAergic system and to be involved in schizophrenia. BNN27 is a novel DHEA derivative, which is devoid of steroidogenic activity. It has recently been reported that BNN27 counteracted schizophrenia-like behavioural deficits produced by glutamate hypofunction in rats.
Objectives
The aim of the present study was to investigate the ability of BNN27 to attenuate non-spatial, spatial recognition and discrete memory deficits induced by apomorphine in rats.
Methods
To this end, the object recognition task (ORT), the object location task (OLT) and the step-through passive avoidance test (STPAT) were used.
Results
BNN27 (3 and 6 mg/kg, i.p.) attenuated apomorphine (0.5 mg/kg, i.p.)-induced non-spatial, spatial recognition and discrete memory deficits. Interestingly, the effects of compounds on memory cannot be ascribed to changes in locomotor activity.
Conclusions
Our findings suggest that BNN27 is effective to DA dysfunction caused by apomorphine, attenuating cognitive impairments induced by this D1/D2 receptor agonist in rats. Additionally, our findings illustrate a functional interaction between BNN27 and the DAergic system that may be of relevance for schizophrenia-like behavioural symptoms.
Similar content being viewed by others
References
Antoniou K, Kafetzopoulos (1991) A comparative study of the behavioral effects of d-amphetamine and apomorphine in the rat. Pharmacol Biochem Behav 39:61–70
Arroyo-Garcia LE, Rodriguez-Moreno A, Flores G (2018) Apomorphine effects on hippocampus. Neural Regen Res 13:2064–2066
Auclair A, Kleven MS, Besnard J, Depoortere R, Newman-Tancredi A (2006) Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology 31:1900–1909
Bennett JP Jr, O’Brien LC, Brohawn DG (2016) Pharmacological properties of microneurotrophin drugs developed for the treatment of amyotrophic lateral sclerosis. Biochem Pharmacol 117:68–77
Bitanihirwe BK, Woo TU (2011) Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 35:878–893
Blochl A, Sirrenberg C (1996) Neurotrophins stimulate the release of dopamine from rat mesencephalic neurons via Trk and p75NTR receptors. J Biol Chem 271:21100–21107
Botsakis K, Mourtzi T, Panagiotakopoulou V, Vreka M, Stathopoulos GT, Pediaditakis I, Charalampopoulos I, Gravanis A, Delis F, Antoniou K, Zisimopoulos D, Georgiou CD, Panagopoulos NT, Matsokis N, Angelatou F (2017) BNN-20, a synthetic microneurotrophin, strongly protects dopaminergic neurons in the “weaver” mouse, a genetic model of dopamine-denervation, acting through the TrkB neurotrophin receptor. Neuropharmacology 121:140–157
Boultadakis A, Pitsikas N (2010) Effects of the nitric oxide synthase inhibitor L-NAME on recognition and spatial memory deficits produced by different NMDA receptor antagonists in the rat. Neuropsychopharmacology 35:2357–2366
Calev A, Venables PH, Monk AF (1983) Evidence for distinct verbal memory pathologies in severely and mildly disturbed schizophrenics. Schizophr Bull 9:247–264
Calogeropoulou T, Avlonitis N, Minas V, Alexi X, Pantzou A, Charalampopoulos I, Zervou M, Vergou V, Katsanou ES, Lazaridis I, Alexis MN, Gravanis A (2009) Novel dehydroepiandrosterone derivatives with antiapopototic activity. J Med Chem 52:6569–6587
Cavoy A, Delacour J (1993) Spatial but not object recognition is impaired by aging in rats. Physiol Behav 53:527–530
Charalampopoulos I, Tsatsanis C, Dermitzaki E, Alexaki VI, Castanas E, Margioris AN, Gravanis A (2004) Dehydroepiandrosterone and allopregnolone protect sympathoadrenal medulla cells against apoptosis via antiapoptotic Bcl-2 proteins. Proc Natl Acad Sci U S A 101:8209–8214
Chrobak JJ, Napier TC (1992) Delayed-non-match-to-sample performance in the radial arm maze: effects of dopaminergic and gabaergic agents. Psychopharmacology 108:72–78
Cools R (2008) Role of dopamine in the motivational and cognitive control of behavior. Neuroscientist 14:381–395
Edwards J, Jackson HJ, Pattison PE (2002) Emotion recognition via facial expression and affective prosody in schizophrenia: a methodological review. Clin Psychol Rev 22:789–832
Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1. Behavioral data. Behav Brain Res 31:47–59
Ennaceur A, Neave N, Aggleton JP (1997) Spontaneous object recognition and object location memory in rats: the effects of lesions in the cingulated cortices, the medial prefrontal cortex, the cingulum bundle and the fornix. Exp Brain Res 113:509–519
Field JR, Walker AG, Conn PJ (2011) Targeting glutamate synapses in schizophrenia. Trends Mol Med 17:689–698
Fiorentini C, Guerra N, Facchetti N, Finardi A, Tiberio L, Schiaffonati L, Spano P, Missale C (2002) Nerve growth factor regulates dopamine D(2) receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-kappaB. Mol Endocrinol 16:353–366
Fletcher PC, Frith CD, Grasby PM, Friston KJ, Dolan RJ (1996) Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia. J Neurosci 16:7055–7062
Freedman R (2003) Schizophrenia. N Engl J Med 349:1738–1749
Friston KJ, Grasby PM, Bench CJ, Frith CD, Cowen PJ, Liddle PF, Frackowiak RSJ, Dolan R (1992) Measuring the neuromodulatory effects of drugs in men with positron emission tomography. Neurosci Lett 141:106–110
Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117–154
Gibbs SE, D’Esposito M (2005) A functional MRI study of the effects of bromocriptine, a dopamine receptor agonist, on component processes of working memory. Psychopharmacology 180:644–653
Glajch KE, Ferraiuolo L, Mueller KA, Stopford MJ, Prabhkar V, Gravanis A, Shaw PJ, Sadri-Vakili G (2016) Microneurotrophins improve survival in motor neuron-astrocyte co cultures but do not improve disease phenotypes in a mutant SOD1 mouse model of amyotrophic lateral sclerosis. PLoS One 11:e0164103
Gourgiotis I, Kampouri NG, Koulouri V, Lempesis IG, Prasinou MD, Georgiadou G, Pitsikas N (2012) Nitric oxide modulates apomorphine-induced recognition memory deficits in rats. Pharmacol Biochem Behav 102:507–514
Grivas V, Markou A, Pitsikas N (2013) The metabotropic glutamate 2/3 receptor agonist LY379268 induces anxiety-like behavior at the highest dose tested in two rat models of anxiety. Eur J Pharmacol 715:105–110
Guazzo EP, Kirpatrick PJ, Goodyer IM, Shiers HM, Herbert J (1996) Cortisol, dehydroepiandrosterone (DHEA) and DHEA sulfate in the cerebrospinal fluid in man: relation to blood levels and the effects of age. J Clin Endocrinol Metab 81:3951–3960
Harris DS, Wolkowitz OM, Reus VI (2001) Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients. World J Biol Psychiatry 2:99–102
Herbener ES (2008) Emotional memory in schizophrenia. Schizophr Bull 34:875–887
Heringa SM, Begemann MJH, Goverde AJ, Sommer IEC (2015) Sex hormones and oxytocin augmentation strategies in schizophrenia: a quantitative review. Schizophr Res 168:603–613
Ibán-Arias R, Lisa S, Mastrodimou N, Kokona D, Koulakis E, Iordanidou P, Kouvarakis A, Fothiadaki M, Papadogkonaki S, Sotiriou A, Katerinopoulos HE, Gravanis A, Charalampopoulos I, Thermos K (2017) The synthetic microneurotrophin BNN27 affects retinal function in rats with streptozotocin-induced diabetes. Diabetes 67:321–333
Ichihara K, Nabeshima T, Kameyama T (1988) Opposite effects induced by low and high doses of apomorphine on single-trial passive avoidance learning in mice. Pharmacol Biochem Behav 30:107–113
Iversen SD, Iversen LL (2007) Dopamine: 50 years in perspective. Trends Neurosci 30:188–193
Kapur S, Remington G (2001) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52:503–517
Kilic FS, Kulluk D, Musmul A (2014) Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice. Neurosciences 19:100–105
King RA, Glasser RL (1970) Duration of electroconvulsive shock-induced retrograde amnesia in rats. Physiol Behav 5:335–339
Kirk RE (1968) Experimental design: procedures for the behavioral science. Brooks/Cole, Belmont
Lazaridis I, Charalamopoulos I, Alexaki VI, Avlonitis N, Pediaditakis I, Efstathopoulos P, Calogeropoulou T, Castanas E, Gravanis A (2011) Neurosteroid dehydroepiandrosterone interacts with nerve growth factor (NGF) receptors, preventing neuronal apoptosis. PLoS Biol 9:e1001051
Lynch G, Staubli V (1991) Possible contributions of long-term potentiation to the encoding and organization of memory. Brain Res 16:204–206
Marx CE, Trost W, Shampine L, Lieberman J, Morrow A, Thakore J (2004) Neuroactive steroids in schizophrenia: relevance to symptoms and therapeutics. Biol Psychiatry 55:171
McGrath J, Saha S, Chant T, Welham J (2008) Schizophrenia: a concise overview of incidence, prevalence and mortality. Epidemiol Rev 30:67–76
Montoya A, Lal S, Menear M, Duplessis E, Thavundayil J, Schmitz N, Lepage M (2008) Apomorphine effects on episodic memory in young healthy volunteers. Neuropsychologia 46:292–300
Moreira JCF, Dal Pizzol F, Bonatto F, Gomez Da Silva E, Flores DG, Picada JN, Roesler R, Pegas Henriques JA (2003) Oxidative damage in brains of mice treated with apomorphine and its oxidized derivative. Brain Res 992:246–251
Nachshoni T, Ebert T, Abramovitch Y, Assael-Amir M, Kotler M, Maayan R, Weizman A, Strous RD (2005) Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophr Res 79:251–256
Ogren SE (1985) Evidence for a role of brain serotonergic neurotransmission in avoidance learning. Acta Physiol Scand 125(Suppl. 544):1–71
Pediaditakis I, Iliopoulos I, Theologidis I, Delivanoglou N, Margioris AN, Charalampopoulos I, Gravanis A (2015) Dehydroepiandrosterone: an ancestral ligand of neurotrophin receptors. Endocrinology 156:16–23
Pediaditakis I, Efstathopoulos P, Prousis KC, Zervou M, Arevalo JC, Alexaki VI, Nikoletopoulou V, Karagianni E, Potamitis C, Tavernarakis N, Chavakis T, Margioris AN, Venihaki M, Calogeropoulou T, Charalampopoulos I, Gravanis A (2016) Selective and differential interactions of BNN27, a novel C17-spiroepoxy steroid derivative, with TrkA receptors, regulating neuronal survival and differentiation. Neuropharmacology 11:266–282
Perez-Neri I, Montes S, Ojeda-Lopez C, Ramirez-Bermudez J, Rios C (2008) Modulation of neurotransmitter systems by dehydroepiandrosterone and dehydroepiandrosterone sulfate: mechanism of action and relevance to psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 32:1118–1130
Picada JN, Schroder N, Izquierdo I, Henriques JAP, Roesler R (2002) Differential neurobehavioral deficits induced by apomorphine and its oxidation product, 8-oxo-apomorphine-semiquinone, in rats. Eur J Pharmacol 443:105–111
Picada JN, Roesler R, Henriques JAP (2005) Genotoxic, neurotoxic and neuroprotective activities of apomorphine and its oxidized derivative 8-oxo-apomorphine. Braz J Med Biol Res 38:477–486
Pitsikas N (2007) Effects of scopolamine and L-NAME on rats’ performance in the object location test. Behav Brain Res 179:294–298
Pitsikas N, Gravanis A (2017) The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts delay-dependent and scopolamine-induced recognition memory deficits in rats. Neurobiol Learn Mem 140:145–153
Pitsikas N, Markou A (2014) The metabotropic glutamate 2/3 receptor agonist LY379268 counteracted ketamine-and apomorphine-induced performance deficits in the object recognition task, but not object location task, in rats. Neuropharmacology 85:27–35
Pitsikas N, Tarantilis PA (2017) Crocins, the active constituents of Crocus sativus L., counteracted apomorphine-induced performance deficits in the novel object recognition task, but not novel object location task, in rats. Neurosci Lett 644:37–42
Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD (2006) Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychopharmacol 26:495–499
Robel P, Boureau E, Corpehot C, Dang DC, Halberg F, Clarke C, Haug M, Schlegel ML, Synguelakis M, Vourch C, Baulieu EE (1987) Neurosteroids: 3β-hydroxy-δ5-derivatives in rata and monkey brain. J Steroid Biochem 27:649–655
Sanchez MG, Bourque M, Morissette M, Di Paolo T (2010) Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16:43–71
Shannon HE, Love PL (2004) Within-session repeated acquisition behavior in rats as a potential model of executive function. Eur J Pharmacol 498:125–134
Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A (2003) Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 60:133–141
Strous RD, Stryjer R, Maayan R, Gal G, Viglin D, Katz E, Eisner D, Weizman A (2007) Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology 32:96–105
Vago DR, Kessner RP (2008) Disruption of the direct perforant path input to the CA1 subregion of the dorsal hippocampus interferes with spatial working memory and novelty detection. Behav Brain Res 189:273–283
Vago DR, Bevan A, Kessner RP (2007) The role of the direct perforant path input to the CA1 subregion of the dorsal hippocampus in memory retention and retrieval. Hippocampus 17:977–987
Van Schijndel JE, Van Loo KM, Van Zweeden M, Djurovic S, Andreassen OA, Hansen T, Werge T, Kallunki P, Pedersen JT, Martens GJ (2009) Three-cohort targeted gene screening reveals a non-synonymous TRKA polymorphism associated with schizophrenia. J Psychiatr Res 43:1195–1199
Van Schijndel JE, Van Zweeden M, Van Loo KM, Djurovic S, Andreassen OA, Hansen T, Werge T, Nyegaard M, Sørensen KM, Nordentoft M, Mortensen PB, Mors O, Børglum AD, Del-Favero J, Norrback KF, Adolfsson R, De Hert M, Claes S, Cichon S, Rietschel M, Nöthen MM, Kallunki P, Pedersen JT, Martens GJ (2011) Dual association of a TRKA polymorphism with schizophrenia. Psychiatr Genet 21:125–131
Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF (2007) Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 10:376–384
Wojtal K, Trojnar MK, Czuczwar SJ (2006) Endogenous neuroprotective factors: neurosteroids. Pharmacol Rep 58:335–340
Xu TX, Sotnikova TD, Liang C, Zhang J, Jung JU, Spealman RD, Gainetdinov RR, Yao WD (2009) Hyperdopaminergic tone erodes prefrontal long-term potential via a D2 receptor operated protein phosphatase gate. J Neurosci 29:14086–14099
Yoo A, Harris J, Dubrovsky B (1996) Dose-response study of dehydroepiandrosterone sulfate on dentate gyrus long term potentiation. Exp Neurol 137:151–156
Zoupa E, Gravanis A, Pitsika N (2019) The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts behavioural deficits induced by the NMDA receptor antagonist ketamine in rats. Neuropharmacology 151:74–83
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Declaration of interests
All authors, except Achille Gravanis, declare that they have not any competing financial interests in relation to the work described. Dr. Achille Gravanis is the co-founder of spin-off Bionature EA LTD, proprietary of compound BNN27 (patented with the WO 2008/ 1555 34 A2 number at the World Intellectual Property Organization).
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The authors declare that the experiments comply with the current laws of Greece.
Rights and permissions
About this article
Cite this article
Pitsikas, N., Zoupa, E. & Gravanis, A. The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts cognitive deficits induced by the D1/D2 dopaminergic receptor agonist apomorphine in rats. Psychopharmacology 238, 227–237 (2021). https://doi.org/10.1007/s00213-020-05672-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-020-05672-z